WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2005118627) GRIFFITHSIN, GLYCOSYLATION-RESISTANT GRIFFITHSIN, AND RELATED CONJUGATES, COMPOSITIONS, NUCLEIC ACIDS, VECTORS, HOST CELLS, METHODS OF PRODUCTION AND METHODS OF USE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2005/118627    International Application No.:    PCT/US2005/018778
Publication Date: 15.12.2005 International Filing Date: 27.05.2005
IPC:
C07K 14/405 (2006.01)
Applicants: GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES [US/US]; Office of Technology Transfer, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852 (US) (For All Designated States Except US).
BOYD, Michael R.; (For US Only).
MORI, Toshiyuki; (For US Only).
O'KEEFE, Barry; (For US Only)
Inventors: BOYD, Michael R.; .
MORI, Toshiyuki; .
O'KEEFE, Barry;
Agent: KISSLING, Heather R.; LEYDIG, VOIT & MAYER, LTD., Two Prudential Plaza, Suite 4900, 180 N. Stetson Avenue, Chicago, Illinois 60601 (US)
Priority Data:
60/576,056 01.06.2004 US
Title (EN) GRIFFITHSIN, GLYCOSYLATION-RESISTANT GRIFFITHSIN, AND RELATED CONJUGATES, COMPOSITIONS, NUCLEIC ACIDS, VECTORS, HOST CELLS, METHODS OF PRODUCTION AND METHODS OF USE
(FR) GRIFFITHSIN, GRIFFITHSIN RESISTANTE A LA GLYCOSYLATION, CONJUGUES, COMPOSITIONS, ACIDES NUCLEIQUES, VECTEURS, CELLULES HOTES, ET METHODES DE PRODUCTION ET D'UTILISATION ASSOCIES
Abstract: front page image
(EN)An isolated and purified nucleic acid molecule that encodes a polypeptide comprising at least eight contiguous amino acids of SEQ ID NO: 3, wherein the at least eight contiguous amino acids have anti-viral activity, as well as an isolated and purified nucleic acid molecule that encodes a polypeptide comprising at least eight contiguous amino acids of SEQ ID NO: 3, wherein the at least eight contiguous amino acids have anti-viral activity, and, when the at least eight contiguous amino acids comprise amino acids 1-121 of SEQ ID NO: 3, the at least eight contiguous amino acids have been rendered glycosylation-resistant, a vector comprising such an isolated and purified nucleic acid molecule, a host cell comprising the nucleic acid molecule, optionally in the form of a vector, a method of producing an anti-viral polypeptide or conjugate thereof, the anti-viral polypeptide itself, a conjugate or fusion protein comprising the anti-viral polypeptide, and compositions comprising an effective amount of the anti-viral polypeptide or conjugate or fusion protein thereof. Further provided are methods of inhibiting prophylactically or therapeutically a viral infection of a host.
(FR)L'invention concerne une molécule d'acide nucléique isolée et purifiée codant un polypeptide comprenant au moins huit acides aminés contigus de SEQ ID NO: 3, ces huit acides aminés contigus présentant une activité antivirale, ainsi qu'une molécule d'acide nucléique isolée et purifiée codant un polypeptide comprenant au moins huit acides aminés contigus de SEQ ID NO: 3, ces huit acides aminés contigus présentant une activité antivirale, et, lorsque ces huit acides aminés contigus comprennent des acides aminés 1-121 de SEQ ID NO: 3, les huit acides aminés contigus sont rendus résistants à la glycosylation. L'invention concerne un vecteur comprenant une telle molécule d'acide nucléique isolée et purifiée, une cellule hôte comprenant la molécule d'acide nucléique, éventuellement sous la forme d'un vecteur. L'invention concerne également une méthode de production d'un polypeptide antiviral ou d'un conjugué de celui-ci, le polypeptide antiviral lui-même, un conjugué ou une protéine hybride comprenant le polypeptide antiviral, et des compositions comprenant une quantité efficace de ce polypeptide antiviral ou de ce conjugué, ou de la protéine hybride de ceux-ci. L'invention concerne encore des méthodes d'inhibition prophylactiques ou thérapeutiques d'une infection virale d'un hôte.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)